Ck20 clone ks20

Manufactured by Agilent Technologies

Sourced in United Kingdom

The CK20 (clone Ks20.8) is an immunohistochemistry (IHC) antibody used for the detection of cytokeratin 20 in tissue samples. Cytokeratin 20 is a type of intermediate filament protein expressed in certain epithelial cells. The CK20 antibody can be utilized in IHC procedures to identify the presence and distribution of cytokeratin 20 in various types of cells and tissues.

Automatically generated - may contain errors

Lab products found in correlation

Close spelling variants of this product

Clone Ks20.8

6 protocols using ck20 clone ks20

CRC Tissue Microarray and Immunohistochemical Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

Tissue microarray (TMA) construction using FFPE tissues from 1370 CRCs was performed. Two different tumour areas in the FFPE tissue samples of each individual CRC case were extracted as two tissue cores (2 mm in diameter) and were transferred to TMA blocks. Immunohistochemical analyses were performed with commercially available antibodies against cytokeratin 7 (CK7; clone OV-TL 12/30, DAKO), cytokeratin 20 (CK20; clone Ks20.8, DAKO) and nuclear protein CDX2 (clone EPR2764Y ready-to-use, CellMarque). For the interpretation of immunohistochemical stain results, cytoplasmic and/or membranous CK7, CK20 and nuclear CDX2 were scored as the percentage of positive tumour cells. The cutoff scores for increased CK7 expression, decreased CK20 expression and decreased CDX2 expression were 10%, 50% and 20%, respectively (Bae et al, 2015 (link)).

Bae J.M., Kim J.H., Kwak Y., Lee D.W., Cha Y., Wen X., Lee T.H., Cho N.Y., Jeong S.Y., Park K.J., Han S.W., Lee H.S., Kim T.Y, & Kang G.H. (2017). Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system. British Journal of Cancer, 116(8), 1012-1020.

+ Open protocol

+ Expand

Immunohistochemical Profiling of Tumor Samples

Check if the same lab product or an alternative is used in the 5 most similar protocols

Immunohistochemical staining was performed on routine sections. The following monoclonal antibodies were used for immunostaining: AE1/AE3 (clone AE1/3, 1:50 dilution; Dako, Carpinteria, CA), CK7 (clone OV-TL 12/30, prediluted; Dako), CK5/6 (D5/16B4 clone, prediluted; Dako), CK20 (clone Ks20.8, prediluted; Dako), synaptophysin (clone DAK-SYNAP, prediluted; Dako), chromogranin (clone LK2H10+PHE5, 1:200 dilution; Thermo Scientific, Waltham, MA), CD56 (clone 123C3, 1:50 dilution; Dako), TTF1 (clone SPT24, prediluted; Leica Biosystems, Buffalo Grove, IL), INSM1 (clone A-8, 1:150; Santa Cruz Biotechnology, Santa Cruz, CA), GATA3 (clone L50-823, 1:100 dilution; Cell Marque, Rocklin, CA), p63 (clone DAK-p63, prediluted; Dako), p40 (clone BC-28, 1:50 dilution; Biocare, Concord, CA), and uroplakin II (clone BC-21, 1:100 dilution; Biocare). Briefly, 4-μm-thick sections were deparaffinized in xylene and hydrated in graded alcohol. Immunostaining was performed using a DAKO autostainer (Agilent, Santa Clara, CA). Slides were incubated with the primary antibody and then with a visualization reagent (secondary goat anti-mouse immunoglobulin and horseradish peroxidase linked to a dextran polymer backbone). The slides were then rinsed with distilled water, incubated with a 3,3-diaminobenzidine substrate-chromogen solution, and subjected to Mayer hematoxylin counterstaining.

Wang G., Yuan R., Zhou C., Guo C., Villamil C., Hayes M., Eigl B.J, & Black P. (2021). Urinary Large Cell Neuroendocrine Carcinoma: A Clinicopathologic Analysis of 22 Cases. The American Journal of Surgical Pathology, 45(10), 1399-1408.

+ Open protocol

+ Expand

Immunohistochemical Profiling of Tumor Samples

Check if the same lab product or an alternative is used in the 5 most similar protocols

FFPE blocks were sectioned and mounted on coated slides (Dako, Glostrup, Denmark) and stained with H&E according to standard protocols. Tumor sections were deparaffinized using EZ-prep (Ventana Medical Systems^®, Tucson, AZ, USA) and immunohistochemistry was performed using the Ventana Benchmark Ultra platform (Ventana Medical Systems) as previously described [33 (link)]. The following primary antibodies were employed: CD117 (polyclonal, 1:100, Dako (Glostrup, Denmark)), CD56 (clone 1B6, 1:50, Novocastra (Newcastle, UK)), chromogranin A (polyclonal, 1:2000, Dako), CK7 (clone OV-TL 12/30),1:1000, Dako), CK20 (clone KS20.8, 1:400, Dako), ki-67 (clone MIB1, 1:100, Dako), MYB (clone EP769Y 1:150 (AbCam, Cambridge, UK), napsin A (clone IP64, 1:400, Novocastra), and TTF-1(clone SPT24, 1:100, Novocastra). MYB was considered positive when nuclear staining was observed in at least 5% of tumor cells [31 (link)]. Positive controls as suggested on datasheets were used. Negative controls omitting the primary antibody were performed for all antibodies.

Andreasen S., Agander T.K., Bjørndal K., Erentaite D., Heegaard S., Larsen S.R., Melchior L.C., Tan Q., Ulhøi B.P., Wessel I, & Homøe P. (2018). Genetic rearrangements, hotspot mutations, and microRNA expression in the progression of metastatic adenoid cystic carcinoma of the salivary gland. Oncotarget, 9(28), 19675-19687.

+ Open protocol

+ Expand

Immunohistochemistry of Colon Tissue

Check if the same lab product or an alternative is used in the 5 most similar protocols

Paraffin-embedded 5 μM sections of distal colon were deparaffinized, rehydrated through graded ethanol, and morphologically checked with H&E. For immunohistochemistry, sections were stained with the following antibodies: monoclonal mouse anti-human cytokeratin 20 (CK20, clone Ks20.8, M7019, Dako, 1:500) and monoclonal mouse anti-E-Cadherin (clone 36, 790-4497, Ventana). All immunostains were performed using Ventana Discovery XT Platform, using CC1 standard regime for CK20 and CC1 mild regime for E-cadherin. Primary antibodies were applied for 60 min followed by biotinylated anti-mouse secondary antibody also for 60 min (Vector, 1:200). Visualization was performed using Ventana DAB map kit. Quantitation of E-cadherin⁺ and CK20⁺ cells was done using Fiji software [13 (link)].

Martin M.L., Zeng Z., Adileh M., Jacobo A., Li C., Vakiani E., Hua G., Zhang L., Haimovitz-Friedman A., Fuks Z., Kolesnick R, & Paty P.B. (2017). Logarithmic expansion of LGR5+ cells in human colorectal cancer. Cellular signalling, 42, 97-105.

+ Open protocol

+ Expand

Immunohistochemical Analysis of HER2 and Other Markers

Check if the same lab product or an alternative is used in the 5 most similar protocols

Immunohistochemical staining for HER2 was performed using the HercepTest™ kit (Dako, Glostrup, Denmark) according to manufacturer's protocols. 4 μm thick sections taken both from original full tumor blocks and the TMA block were used for HER2 IHC. HER2 protein expression was scored as 0, 1+, 2+, and 3+ according to the ASCO/CAP 2013 HER2 test guideline [26 (link)]. HER2 IHC 3+ was considered to be HER2-positive, IHC 2+ HER2-equivocal, and IHC 0 and 1+ HER2-negative [26 (link)]. Additional immunohistochemical staining for cytokeratin (CK) 7 (clone OV-TL 12/30; Dako), CK20 (clone Ks20.8; Dako), p53 (clone DO7; Dako), p63 (clone 4A4; Ventana), and CD138 (clone 5F7; Novocastra) was also performed on sections taken from the TMA block. All IHC were performed using Ventana Benchmark XT automated staining system (Ventana Medical Systems, Tucson, AZ).

Kim B., Kim G., Song B., Lee C., Park J.H, & Moon K.C. (2016). HER2 Protein Overexpression and Gene Amplification in Plasmacytoid Urothelial Carcinoma of the Urinary Bladder. Disease Markers, 2016, 8463731.

+ Open protocol

+ Expand

Immunohistochemical Profiling of Cell Samples

Check if the same lab product or an alternative is used in the 5 most similar protocols

Immunohistochemistry (IHC) was performed on the cell block samples and/or concurrent core biopsy/surgical resection specimen. The IHC studies performed included: TTF‐1 (clone 867G311, Dako, Carpinteria, CA), SALL4 (clone EE‐30, Santa Cruz, Dallas, Texas), CDX2 (clone AMT28, Novocastra, Leica Biosystems, Buffalo Grove, IL), CK7 (clone OV‐TL, Dako, Carpinteria, California), CK20 (clone K_s20.8, Dako, Carpinteria, CA), synaptophysin (clone 27G12, Leica, Buffalo Grove, IL), chromogranin (clone LK2H10, ThermoFisher Scientific, Pittsburgh, PA), p53 (clone DO‐1, Calbiochem, Temecula, CA), and PD‐L1 (clone 22C3 pharmDx, Dako, Carpinteria, CA). PD‐L1 expression was determined using tumor proportion score as described in the manufacturer's interpretation manual. All IHCs were clinically validated for use in alcohol‐fixed and formalin‐fixed specimens and performed at a dilution of 1:50 using validated protocols on either Leica BOND‐III (Leica Biosystems, Buffalo Grove, IL) or BenchMark X.T. Ventana platforms (Roche, Tucson, AZ).

Mendoza R.P., Chen‐Yost H.I., Wanjari P., Wang P., Symes E., Johnson D.N., Reeves W., Mueller J., Antic T, & Biernacka A. (2024). Lung adenocarcinomas with isolated TP53 mutation: A comprehensive clinical, cytopathologic and molecular characterization. Cancer Medicine, 13(1), e6873.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!